サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1289782

子宮頸がん診断の世界市場-2023-2030

Global Cervical Cancer Diagnostics Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
子宮頸がん診断の世界市場-2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

子宮頸がん診断の世界市場規模は2022年に81億米ドルに達し、2030年には最大130億米ドルに達することで有利な成長が予測されています。子宮頸がん診断市場は、2023-2030年の予測期間中に6.3%のCAGRを示すと予測されています。

子宮頸がん診断の一環として、子宮頸がんや前がん疾患の診断やモニタリングには、さまざまな検査や技術が採用されています。子宮頸がんのステージを確認するために、リンパ節生検、膀胱鏡検査、肛門鏡検査、PET-CT（Positron Emission Tomography-computed tomography）のような画像検査などの追加の処置が実施されます。

市場力学

活発な主要プレーヤーと子宮頸がん診断製品の発売が、予測期間中の世界の子宮頸がん診断市場の成長を後押ししています

女性にとって、子宮頸がんは典型的な悪性腫瘍です。近年、罹患率や死亡率の増加とともに、明らかに若返りの傾向が見られます。病因が明確で、早期発見で治る可能性があるがんは、子宮頸がんだけです。例えば、New Horizon Health社が開発したCerviClearテストは、世界初の尿によるHPV検出と子宮頸がんスクリーニングテストです。

非侵襲的な家庭用尿自己採取を実現し、14種類の高リスクHPVウイルスすべてを完全にカバーする唯一のソリューションです。本製品は、すでにCEマークを取得しているため、香港およびグレーターベイエリアでの導入が可能です。

子宮頸がんに関する消費者の意識の高まりが、予測期間中の世界の子宮頸がん診断市場の成長を後押ししています

子宮頸がんは最も予防可能ながんの一つであり、毎年インドの女性の間で77,000人近くの死因を占めています。例えば、2023年4月、がんの認知、予防、早期発見の促進を目的とした非営利団体であるCancer Awareness Prevention and Early Detection Trust（CAPED）とRoche Diagnostics Indiaは、覚書を交わしました（MoU）。

CAPEDとの関係は、子宮頸がんという病気にまつわる社会的スティグマを取り除き、子宮頸がん検診に対する意識を高めるためのロシュ・ダイアグノスティックス・インドの最近の取り組みの一つです。ロシュ・ダイアグノスティックス・インドは、国際的に子宮頸がんの発症率を低下させることに尽力しています。

診断検査費用の高さが、予測期間における世界の子宮頸がん診断市場の成長を妨げています

子宮頸がん診断検査の価格は、特定の検査、場所、医療施設の環境、存在する医療システムなど、いくつかの変数によって変化する可能性があります。パップテストは、場所やヘルスケア専門家によって、20ドルから100ドルの費用がかかることがあります。

また、HPV DNA検査は、検査機関や正確な検査方法によって異なりますが、50ドルから200ドル以上の費用がかかります。コルポスコピー検査は、地域やヘルスケア専門家、検査中に行われる追加処置によって、200ドルから800ドルの費用がかかる場合があります。

COVID-19の影響分析

COVID-19の大流行は、子宮頸がん診断市場に大きな影響を与えました。パンデミックはヘルスケアシステムに圧力をかけ、子宮頸がん診断サービスの利用を制限しています。

パップスメア検査、HPV検査、コルポスコピー、生検などの診断検査の遅れは、リソースの不足、医療機関の過度の負担、COVID-19対応業務への労働者の振り分けが原因であるとされています。

2023年現在、COVID-19の状況は回復し、すべての患者がヘルスケア施設にアクセスできるようになり、子宮頸がん診断市場を牽引しています。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が子宮頸がん診断市場に与える影響は複雑で多面的です。戦闘によって人々が避難し、交通機関が寸断され、軍の検問所が設置される可能性があります。これらの障害により、医療施設へのアクセスが制限され、人々が子宮頸がん診断やその他のヘルスケアサービスを迅速に受けることが困難になる可能性があります。

さらに、紛争時にはヘルスケアの資源や努力が、外傷治療、緊急対応、緊急医療ニーズに集中するよう方向転換されました。その結果、啓発キャンペーンや子宮頸がん検診プログラムなど、検診率の低下や診断の先送りを招くような公衆衛生対策が減少しています。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 子宮頸がん罹患率の増加
    • 抑制要因
      • 診断検査にかかるコストの高さ
    • 機会
      • 技術的な進歩
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 法規制分析

第6章 COVID-19の分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能の分析

第9章 検査タイプ別

  • パップスメア検査
  • HPV DNA検査
  • 大腸内視鏡検査
  • EEC検査
  • その他

第10章 年齢層別

  • 21歳以下
  • 21～29
  • 30～65
  • 65歳以上

第11章 流通チャネル別

  • 病院薬局
  • 病院内薬局
  • eコマース

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • QIAGEN
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Olympus
  • Cardinal Health
  • Siemens Healthcare
  • Hologic, Inc.
  • Quest Diagnostics
  • Abbott Laboratories

第15章 付録

目次
Product Code: CD1901

Market Overview

The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.

A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.

Market Dynamics

Active Major Players and Cervical Cancer Diagnostic Product Launches are Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.

It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.

The Growing Awareness Among Consumers About Cervical Cancer is Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).

The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.

The High Cost of Diagnostic Tests is Hampering the Global Cervical Cancer Diagnostics Market Growth in the Forecast Period.

The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.

In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.

Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.

As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.

In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.

Segment Analysis

The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.

The HPV DNA Test Segment is Expected to Hold the 2nd Dominant Position in the Market Over the Forecast Period.

The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.

For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.

Geographical Analysis

Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.

North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).

White women in the South aged 40-44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.

Competitive Landscape

The major global players in the market include: QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.

Why Purchase the Report?

  • To visualize the global cervical cancer diagnostics market segmentation based on the test type, age group, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Cervical Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnostic tests
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advances
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 9.1.2. Market Attractiveness Index, By Test Type
  • 9.2. Pap Smear Test*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. HPV DNA Test
  • 9.4. Coloscopy
  • 9.5. EEC Test
  • 9.6. Others

10. By Age Group

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.1.2. Market Attractiveness Index, By Age Group
  • 10.2. Below 21*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. 21-29
  • 10.4. 30-65
  • 10.5. 65 and Above

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Hospital Pharmacies
  • 11.4. E-Commerce

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. QIAGEN*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Becton, Dickinson and Company
  • 14.3. F. Hoffmann-La Roche Ltd.
  • 14.4. Guided Therapeutics
  • 14.5. Olympus
  • 14.6. Cardinal Health
  • 14.7. Siemens Healthcare
  • 14.8. Hologic, Inc.
  • 14.9. Quest Diagnostics
  • 14.10. Abbott Laboratories

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us